OBJECTIVE: To quantify the relative risk reductions achieved with different regimens to lower blood pressure in younger and older adults. DESIGN: Meta-analyses and meta-regression analyses used to compare the effects on the primary outcome between two age groups (<65 v > or =65 years). Evidence for an interaction between age and the effects of treatment sought by fitting age as a continuous variable and estimating overall effects across trials. PRIMARY OUTCOME: total major cardiovascular events. RESULTS: 31 trials, with 190 606 participants, were included. The meta-analyses showed no clear difference between age groups in the effects of lowering blood pressure or any difference between the effects of the drug classes on major cardiovascular events (all P> or =0.24). Neither was there any significant interaction between age and treatment when age was fitted as a continuous variable (all P>0.09). The meta-regressions also showed no difference in effects between the two age groups for the outcome of major cardiovascular events (<65 v > or =65; P=0.38). CONCLUSIONS: Reduction of blood pressure produces benefits in younger (<65 years) and older (> or =65 years) adults, with no strong evidence that protection against major vascular events afforded by different drug classes varies substantially with age.
OBJECTIVE: To quantify the relative risk reductions achieved with different regimens to lower blood pressure in younger and older adults. DESIGN: Meta-analyses and meta-regression analyses used to compare the effects on the primary outcome between two age groups (<65 v > or =65 years). Evidence for an interaction between age and the effects of treatment sought by fitting age as a continuous variable and estimating overall effects across trials. PRIMARY OUTCOME: total major cardiovascular events. RESULTS: 31 trials, with 190 606 participants, were included. The meta-analyses showed no clear difference between age groups in the effects of lowering blood pressure or any difference between the effects of the drug classes on major cardiovascular events (all P> or =0.24). Neither was there any significant interaction between age and treatment when age was fitted as a continuous variable (all P>0.09). The meta-regressions also showed no difference in effects between the two age groups for the outcome of major cardiovascular events (<65 v > or =65; P=0.38). CONCLUSIONS: Reduction of blood pressure produces benefits in younger (<65 years) and older (> or =65 years) adults, with no strong evidence that protection against major vascular events afforded by different drug classes varies substantially with age.
Authors: M J Brown; J K Cruickshank; A F Dominiczak; G A MacGregor; N R Poulter; G I Russell; S Thom; B Williams Journal: J Hum Hypertens Date: 2003-02 Impact factor: 3.012
Authors: Giuseppe Mancia; Guy De Backer; Anna Dominiczak; Renata Cifkova; Robert Fagard; Giuseppe Germano; Guido Grassi; Anthony M Heagerty; Sverre E Kjeldsen; Stephane Laurent; Krzysztof Narkiewicz; Luis Ruilope; Andrzej Rynkiewicz; Roland E Schmieder; Harry A J Struijker Boudier; Alberto Zanchetti; Alec Vahanian; John Camm; Raffaele De Caterina; Veronica Dean; Kenneth Dickstein; Gerasimos Filippatos; Christian Funck-Brentano; Irene Hellemans; Steen Dalby Kristensen; Keith McGregor; Udo Sechtem; Sigmund Silber; Michal Tendera; Petr Widimsky; José Luis Zamorano; Serap Erdine; Wolfgang Kiowski; Enrico Agabiti-Rosei; Ettore Ambrosioni; Lars H Lindholm; Margus Viigimaa; Stamatis Adamopoulos; Enrico Agabiti-Rosei; Ettore Ambrosioni; Vicente Bertomeu; Denis Clement; Serap Erdine; Csaba Farsang; Dan Gaita; Gregory Lip; Jean-Michel Mallion; Athanasios J Manolis; Peter M Nilsson; Eoin O'Brien; Piotr Ponikowski; Josep Redon; Frank Ruschitzka; Juan Tamargo; Pieter van Zwieten; Bernard Waeber; Bryan Williams Journal: J Hypertens Date: 2007-06 Impact factor: 4.844
Authors: B Williams; N R Poulter; M J Brown; M Davis; G T McInnes; J F Potter; P S Sever; S McG Thom Journal: J Hum Hypertens Date: 2004-03 Impact factor: 3.012
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: Nadia A Khan; Brenda Hemmelgarn; Raj Padwal; Pierre Larochelle; Jeff L Mahon; Richard Z Lewanczuk; Finlay A McAlister; Simon W Rabkin; Michael D Hill; Ross D Feldman; Ernesto L Schiffrin; Norman R C Campbell; Alexander G Logan; Malcolm Arnold; Gordon Moe; Tavis S Campbell; Alain Milot; James A Stone; Charlotte Jones; Lawrence A Leiter; Richard I Ogilvie; Robert J Herman; Pavel Hamet; George Fodor; George Carruthers; Bruce Culleton; Kevin D Burns; Marcel Ruzicka; Jacques deChamplain; George Pylypchuk; Norm Gledhill; Robert Petrella; Jean-Martin Boulanger; Luc Trudeau; Robert A Hegele; Vincent Woo; Phil McFarlane; Rhian M Touyz; Sheldon W Tobe Journal: Can J Cardiol Date: 2007-05-15 Impact factor: 5.223
Authors: Nigel S Beckett; Ruth Peters; Astrid E Fletcher; Jan A Staessen; Lisheng Liu; Dan Dumitrascu; Vassil Stoyanovsky; Riitta L Antikainen; Yuri Nikitin; Craig Anderson; Alli Belhani; Françoise Forette; Chakravarthi Rajkumar; Lutgarde Thijs; Winston Banya; Christopher J Bulpitt Journal: N Engl J Med Date: 2008-03-31 Impact factor: 91.245
Authors: Joel Neutel; Dean J Kereiakes; Kathy A Stoakes; Jen-Fue Maa; Ali Shojaee; William F Waverczak Journal: Drugs Aging Date: 2011-06-01 Impact factor: 3.923
Authors: Carlos Maria Ferrario; Sarfaraz Ahmad; Sayaka Nagata; Stephen W Simington; Jasmina Varagic; Neal Kon; Louis Joseph Dell'italia Journal: Clin Sci (Lond) Date: 2014-04 Impact factor: 6.124
Authors: Linda M Gerber; Samuel J Mann; Margaret V McDonald; Ya-Lin Chiu; Sridevi Sridharan; Penny H Feldman Journal: Am J Hypertens Date: 2012-12-28 Impact factor: 2.689
Authors: K Stamatelopoulos; D Bramos; E Manios; E Alexaki; A Kaladaridou; G Georgiopoulos; E Koroboki; A Kolyviras; K Stellos; N Zakopoulos; S Toumanidis Journal: J Hum Hypertens Date: 2013-11-28 Impact factor: 3.012